Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06170788 · ClinicalTrials.gov registry record · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
A Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
- 20
- Study locations
NCT06170788 is a Phase 3 study of Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 614 participants, above the 278-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (121% higher). The trial reports 20 study locations across 19 states.
The verdict
NCT06170788, a Phase 3 study of Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- BIOLOGICAL Pembrolizumab
- DRUG Supportive care measures
Study Locations (20)
Minnesota
- Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) - Minneapolis
- Mayo Clinic - Rochester ( Site 0148) - Rochester
Arizona
- Mayo Clinic in Arizona - Phoenix ( Site 0147) - Phoenix
California
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) - Burbank
Colorado
- Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) - Grand Junction
Florida
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) - Jacksonville
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) - Marietta
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 0121) - Louisville
Maine
- New England Cancer Specialists ( Site 0143) - Westbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2030-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06170788
The ClinicalTrials.gov registry entry for NCT06170788 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 278-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (121% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT06170788 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Minnesota, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06170788 about?
NCT06170788 is a clinical study titled "Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)". The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respe...
What is the current status of trial NCT06170788?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2023-12-15. Estimated completion is 2030-05-27.
What conditions does trial NCT06170788 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06170788?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Pembrolizumab (BIOLOGICAL), Supportive care measures (DRUG).
Who is sponsoring clinical trial NCT06170788?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06170788 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
RECRUITING · Phase 3
-
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
RECRUITING · Phase 3
-
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.